ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
Ernexa Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.98−0.11 (-5.26%)
Close on Oct 19, 2026
- Market cap
- $2.34M
- P/E (TTM)
- –
- Dividend yield
- –
Ernexa Therapeutics Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subscription Revenue [Member] | $4.88M | $14.28M | $16.03M | $16.95M | – | – | – | – | – | – | 84.2% | -65.8% |
| Other Revenue [Member] | $492.00K | $3.18M | $3.72M | $3.56M | – | – | – | – | – | – | 8.5% | -84.5% |
| Hardware Revenue [Member] | $426.00K | $2.35M | $3.59M | $770.00K | – | – | – | – | – | – | 7.3% | -81.9% |
By region
| Revenue | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States [Member] | $5.48M | $19.15M | $22.65M | $20.57M | $21.56M | $23.68M | $24.92M | $22.48M | $22.55M | $21.93M | 94.5% | -71.4% |
| Canada [Member] | $320.00K | $653.00K | $682.00K | $704.00K | $753.00K | $841.00K | $1.13M | $1.27M | $1.51M | $1.94M | 5.5% | -51.0% |
From the segment and revenue-disaggregation notes of Ernexa Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.